SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

CAC 40 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Sanofi-Aventis: Click to view the issuer\'s details

Last update : 29/03/2019  >View issuer details

2021.07.22 | 18:02 | Share History / Voting Rights and Number of Shares

English version HTML (w) Mail

puce Sanofi: Information concerning the total number of voting rights and shares - June 2021 - HTML (w)

2021.07.22 | 18:02 | Share History / Voting Rights and Number of Shares

French version HTML (w) Mail

puce Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juin 2021 - HTML (w)

2021.07.13 | 07:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris - HTML (w)

2021.07.13 | 07:30 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi devient partenaire Premium des Jeux Olympiques et Paralympiques de Paris 2024 - HTML (w)

2021.06.30 | 18:00 | Share History / Voting Rights and Number of Shares

English version HTML (w) Mail

puce Sanofi: Information concerning the total number of voting rights and shares - May 2021 - HTML (w)

2021.06.30 | 18:00 | Share History / Voting Rights and Number of Shares

French version HTML (w) Mail

puce Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2021 - HTML (w)

2021.06.29 | 10:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi launches dedicated vaccines mRNA Center of Excellence - HTML (w)

2021.06.29 | 10:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi annonce la création d’un Centre d’excellence dédié aux vaccins à ARNm - HTML (w)

2021.06.28 | 08:00 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial - HTML (w)

2021.06.28 | 08:00 | Permanent Information Releases / Sales and Revenues

French version HTML (w) Mail

puce Premiers résultats positifs pour le nirsevimab contre le VRS dans le cadre de l’essai MEDLEY de phase II/III - HTML (w)

2021.06.25 | 07:30 | Permanent Information Releases / Notification of availability

English version HTML (w) Mail

puce Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes - HTML (w)

2021.06.25 | 07:30 | Permanent Information Releases / Notification of availability

French version HTML (w) Mail

puce Sanofi : Mise en ligne du document «Q2 2021 Memorandum for modelling purposes» - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 3114